who owns the patent for retatrutide Retatrutide, an investigational triple hormone receptor agonist that shows promise weight loss in ongoing phase-3 clinical trials, is being sold openly across internet and prescribed by licensed physicians online and Want to learn more about
Description
Can it improve metabolic health
Pregnant or breastfeeding mother Women who are pregnant or breastfeeding should avoid estrogen or GH, as its effects in these conditions have not been well studied
Most patients need to continue treatment indefinitely to maintain weight loss
Retained gastric contents Case reports and perioperative observations have described patients taking semaglutide or other GLP-1 therapies who had retained gastric contents despite fasting
Treatment duration varies by patient
Retatrutide is an investigational peptide currently being studied for its interaction with multiple metabolic receptor pathways
